Evidence for a selective loss of somatostatin receptor subtype expression in male germ cell tumors of seminoma type

• Published in: Carcinogenesis (New York) Vol. 21; no. 4; pp. 805 - 810
• Main Authors: Baou, Najima, Bouras, Mourad, Droz, Jean-Pierre, Benahmed, Mohamed, Krantic, Slavica
• Format: Journal Article
• Language: English
• Published: Oxford Oxford University Press 01.04.2000; Oxford Publishing Limited (England)
• Subjects: Adult; Biological and medical sciences; central nervous system; CNS; Gynecology. Andrology. Obstetrics; Humans; Male; Male genital diseases; Medical sciences; Middle Aged; MMLV; Moloney monkey leukemia virus; Receptors, Somatostatin - classification; Receptors, Somatostatin - genetics; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger - analysis; Seminoma - metabolism; somatostatin; SRIF; Testicular Neoplasms - metabolism; Testis - chemistry; Tumors; Human; Cell proliferation; Selectivity; Case control study; Malignant tumor; Anticarcinogen; Germinal cell; Gene expression; Testicle; Carcinogenesis; Seminoma; Molecular epidemiology; Somatostatin; Male genital diseases; Subtype; Testicular diseases; Hormonal receptor
• ISSN: 0143-3334; 1460-2180
• DOI: 10.1093/carcin/21.4.805

Somatostatin (SRIF) is a potent antiproliferative signal for both normal and tumoral mammalian cells and an alteration in the SRIF receptor expression pattern has been associated with carcinogenesis. In the present study, the relevance of SRIF signaling to human male germ cell tumors was assessed at the receptor level. The expression of five SRIF receptor (sst1–sst5) mRNAs was estimated by RT–PCR and compared between normal and tumoral testes. All 12 normal testicular tissues studied contained sst3 and sst5 receptor transcripts whereas sst4 was present in almost all (11 of 12). sst1 transcripts were consistently absent while the majority (11/12) of normal samples studied did not contain sst2 mRNA. Parallel assessment of SRIF receptor mRNAs in 10 seminoma testicular germ cell tumors showed expression of a single receptor type, sst5, in all samples analyzed. All seminoma samples were depleted in transcripts corresponding to sst1 and sst2 receptors while either sst3 or sst4 mRNAs were absent in almost all (9 of 10) tumoral samples studied. The comparison of SRIF receptor expression between normal tissue and seminoma tumors thus points to a selective loss of sst3 and sst4 mRNA expression in seminomas. Altogether these data indicate that: (i) normal human testes are putative SRIF targets; (ii) loss of sst3 and sst4 SRIF receptor expression might be associated with seminoma carcinogenesis.